Further Information
Campath^® (alemtuzumab) is approved as a single agent for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL). It binds to the CD52 antigen, which is present on the surface of B and T lymphocytes and other cells. After binding to the CD52 antigen present on the surface of leukaemic cells, it destroys them.

In a completed Phase II trial comparing Campath^® with Rebif^® (interferon beta-1a) for the treatment of MS, Campath^® was found to have a significant treatment effect that lasted for the three-year duration of the study. Patients taking Campath^® experienced a 73% reduction in the risk for relapse and at least a 70% reduction in the risk for progression of clinically significant disability compared with patients treated with Rebif^®.

Two Phase III trials are fully enrolled. One is comparing Campath^® to Rebif^® as a first-line therapy for patients with relapsing-remitting MS, and the second patients who have continued to experience relapse episodes while on currently available disease modifying therapies.

Data are anticipated in 2011, with potential approval in 2012.